Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico.

Tilghman MW, Guerena DD, Licea A, Pérez-Santiago J, Richman DD, May S, Smith DM.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e70-4. doi: 10.1097/QAI.0b013e3181ff63d7.

2.

Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.

van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D.

Clin Infect Dis. 2011 Jan 15;52(2):264-70. doi: 10.1093/cid/ciq084.

3.

Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection in Seoul, South Korea.

Kim SB, Kim HW, Kim HS, Ann HW, Kim JK, Choi H, Kim MH, Song JE, Ahn JY, Ku NS, Oh DH, Kim YC, Jeong SJ, Han SH, Kim JM, Smith DM, Choi JY.

Scand J Infect Dis. 2014 Feb;46(2):136-40. doi: 10.3109/00365548.2013.851415. Epub 2013 Nov 15.

4.

The use of pooled viral load testing to identify antiretroviral treatment failure.

Smith DM, May SJ, Pérez-Santiago J, Strain MC, Ignacio CC, Haubrich RH, Richman DD, Benson CA, Little SJ.

AIDS. 2009 Oct 23;23(16):2151-8. doi: 10.1097/QAD.0b013e3283313ca9.

5.

Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique.

Tilghman M, Tsai D, Buene TP, Tomas M, Amade S, Gehlbach D, Chang S, Ignacio C, Caballero G, Espitia S, May S, Noormahomed EV, Smith DM.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):256-61. doi: 10.1097/QAI.0000000000000724.

6.

Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children.

Chohan BH, Tapia K, Merkel M, Kariuki AC, Khasimwa B, Olago A, Gichohi R, Obimbo EM, Wamalwa DC.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):e87-93. doi: 10.1097/QAI.0b013e318292f9cd.

7.

Pooled HIV-1 viral load testing using dried blood spots to reduce the cost of monitoring antiretroviral treatment in a resource-limited setting.

Pannus P, Fajardo E, Metcalf C, Coulborn RM, Durán LT, Bygrave H, Ellman T, Garone D, Murowa M, Mwenda R, Reid T, Preiser W.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):134-7. doi: 10.1097/QAI.0b013e3182a61e63.

8.

Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

May S, Gamst A, Haubrich R, Benson C, Smith DM.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):194-201. doi: 10.1097/QAI.0b013e3181ba37a7.

9.

A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.

Newman H, Breunig L, van Zyl G, Stich A, Preiser W.

J Clin Virol. 2014 Aug;60(4):387-91. doi: 10.1016/j.jcv.2014.05.011. Epub 2014 May 29.

PMID:
24929754
10.

Prevalence and predictive value of intermittent viremia with combination hiv therapy.

Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK.

JAMA. 2001 Jul 11;286(2):171-9.

PMID:
11448280
11.

Challenges and opportunities for the implementation of virological testing in resource-limited settings.

Roberts T, Bygrave H, Fajardo E, Ford N.

J Int AIDS Soc. 2012 Oct 9;15(2):17324. doi: 10.7448/IAS.15.2.17324. Review.

12.

Measures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals.

Rutstein SE, Kamwendo D, Lugali L, Thengolose I, Tegha G, Fiscus SA, Nelson JA, Hosseinipour MC, Sarr A, Gupta S, Chimbwandira F, Mwenda R, Mataya R.

J Clin Virol. 2014 Aug;60(4):392-8. doi: 10.1016/j.jcv.2014.05.005. Epub 2014 May 22.

13.

A combined screening platform for HIV treatment failure and resistance.

Tilghman MW, May S, Pérez-Santiago J, Ignacio CC, Little SJ, Richman DD, Smith DM.

PLoS One. 2012;7(4):e35401. doi: 10.1371/journal.pone.0035401. Epub 2012 Apr 26.

14.

Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.

Bronze M, Aitken SC, Wallis CL, Steegen K, Stuyver LJ, de Wit TF, Stevens W.

J Virol Methods. 2013 Dec;194(1-2):300-7. doi: 10.1016/j.jviromet.2013.08.015. Epub 2013 Aug 28.

PMID:
23994150
15.

Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.

Chang LW, Harris J, Humphreys E.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008494. doi: 10.1002/14651858.CD008494. Review.

PMID:
20393969
16.

Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.

Gerlach J, Sequeira M, Alvarado V, Cerpas C, Balmaseda A, Gonzalez A, de Los Santos T, Levin CE, Amador JJ, Domingo GJ.

J Int AIDS Soc. 2010 Nov 5;13:43. doi: 10.1186/1758-2652-13-43.

17.

Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda.

Waters L, Kambugu A, Tibenderana H, Meya D, John L, Mandalia S, Nabankema M, Namugga I, Quinn TC, Gazzard B, Reynolds SJ, Nelson M.

J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):590-3.

PMID:
18193501
18.

Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy.

Rottinghaus EK, Ugbena R, Diallo K, Bassey O, Azeez A, Devos J, Zhang G, Aberle-Grasse J, Nkengasong J, Yang C.

Clin Infect Dis. 2012 Apr;54(8):1187-95. doi: 10.1093/cid/cis015. Epub 2012 Mar 12.

PMID:
22412066
19.

Short communication: prospective comparison of qualitative versus quantitative polymerase chain reaction for monitoring virologic treatment failure in HIV-infected patients.

Jeong SJ, Kim MH, Song JE, Ahn JY, Kim SB, Ann HW, Kim JK, Choi H, Ku NS, Han SH, Kim JM, Smith DM, Kim HS, Choi JY.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):827-9. doi: 10.1089/AID.2013.0227. Epub 2014 May 15.

20.

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP; Stratall ANRS 12110/ESTHER Study Group.

Lancet Infect Dis. 2013 Jul;13(7):577-86. doi: 10.1016/S1473-3099(13)70073-2. Epub 2013 Apr 18.

PMID:
23602084

Supplemental Content

Support Center